Skip to main content
SpringerLink
Log in

Chemotherapy and Radiotherapy of Gastrointestinal Tumors

  • Book
  • © 1981

Overview

Editors:
  1. Hans Otto Klein

    1. Medizinische Universitätsklinik, Köln 41, Germany

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Recent Results in Cancer Research (RECENTCANCER, volume 79)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (11 chapters)

  1. Front Matter

    Pages I-VII
    Download chapter PDF

  2. The Importance of Lectin Binding Sites and Carcinoembryonic Antigen with Regard to Normal, Hyperplastic, Adenomatous, and Carcinomatous Colonic Mucosa

    • P. J. Klein, R. Osmers, M. Vierbuchen, M. Ortmann, J. Kania, G. Uhlenbruck
    Pages 1-9

  3. Why Do Colon Tumours Respond Poorly to Chemotherapeutic Agents?

    • L. M. van Putten, E. A. Sluijter, T. Smink, J. H. Mulder
    Pages 10-18

  4. Prospective and Controlled Studies on Multidisciplinary Treatment in Gastrointestinal Cancer

    • A. Gérard, M. Gignoux, A. Roussel, J. C. Goffin, A. Brugarolas, P. Zeitoun et al.
    Pages 19-27

  5. Recent Results of Clinical Therapeutic Trials for Gastrointestinal Malignancies Conducted in the United States

    • D. L. Kisner, P. S. Schein, J. S. Macdonald
    Pages 28-40

  6. Effectiveness of Postoperative Adjuvant Therapy with Cytotoxic Chemotherapy (Cytosine Arabinoside, Mitomycin C, 5-Fluorouracil) or Immunotherapy (Neuraminidase-Modified Allogeneic Cells) in the Prevention of Recurrence of Duke’s B and C Colon Cancer

    • H. Rainer, E. Kovats, H. G. Lehmann, M. Micksche, R. Rauhs, H. H. Sedlacek et al.
    Pages 41-47

  7. A Controlled Prospective Trial of Adjuvant Razoxane in Resectable Colorectal Cancer

    • J. M. Gilbert, P. C. Cassell, H. Ellis, C. Wastell, K. Hellmann, M. G. Evans et al.
    Pages 48-58

  8. Methyl-CCNU and Ftorafur in Treatment of Rectosigmoidal Tumors and Ftorafur Capsules in Treatment of Colorectal Tumors

    • Z. Mechl, A. Malíř
    Pages 59-64

  9. High-Dose Therapy with Ftorafur in Gastrointestinal Cancer

    • H. O. Klein, P. D. Wickramanayake, R. Voigtmann, Th. Löffler, R. Mohr, H. Oerkermann
    Pages 65-81

  10. Comparison of Ftorafur with 5-Fluorouracil in Combination Chemotherapy of Advanced Gastrointestinal Carcinoma

    • W. Queißer, G. Schnitzler, J. Schaefer, H. Arnold, P. Drings, D. Fritze et al.
    Pages 82-92

  11. Efficacy of Dacarbazine Imidazole Carboxamide and Mitomycin C Combination Therapy in Patients with Adenocarcinoma of the Colon Refractory to 5-Fluorouracil Therapy

    • J. F. Conroy, P. I. Roda, I. Brodsky, S. B. Kahn, S. I. Bulova, E. Pequignot
    Pages 93-100

  12. 5-Fluorouracil: A Comparative Pharmacokinetic Study and Preliminary Results of a Clinical Phase I Study

    • J. P. Obrecht, W. Weber, J. P. Cano, Ch. Crevoisier, P. Alberto, I. Forgo et al.
    Pages 101-107

  13. Back Matter

    Pages 109-114
    Download chapter PDF
Back to top

Keywords

About this book

Attempts to influence survival of patients with colorectal cancer (CRC) by adjuvant chemotherapy are limited by the variability of survival in different prognostic groups [4] and the paucity of drugs that have shown activity in the advanced disease [10]. Of the few drugs which are active in the advanced disease, only 5-fluorouracil (5-FU) and razoxane «±1,2-bis(3,4-dioxopiperazin-1-yl)propane) are suitable for long-term adjuvant treatment [2, 9]. 5-FU has been widely and intensively studied as adjuvant chemotherapy in CRC [7], but there is no unanimity that it has even the marginal influence on survival that has been claimed [3, 10]. Razoxane has not previously been tested for adjuvant or maintenance treatment in CRC. It has however a number of biological activities which might be thought useful in the treatment of residual or minimal tumours [1] and which might therefore make it useful as an adjuvant. Thus it specifically prevents tumour dissemination and metastases in some tumours and normalizes the neovasculature which the tumours induce [6, 8, 11]. The drug is not cytotoxic in the usual sense, does not affect non-dividing cells, and only blocks cell division during a brief period of the cell cycle in late G and/or early mitosis [12]. It does so non-selectively and most cells capable of 2 division examined so far have been affected by the drug. Even affected cells however are not destroyed immediately, but may increase in size and become multinucleate [5].

Editors and Affiliations

  • Medizinische Universitätsklinik, Köln 41, Germany

    Hans Otto Klein

Bibliographic Information

  • Book Title: Chemotherapy and Radiotherapy of Gastrointestinal Tumors

  • Editors: Hans Otto Klein

  • Series Title: Recent Results in Cancer Research

  • DOI: https://doi.org/10.1007/978-3-642-81681-9

  • Publisher: Springer Berlin, Heidelberg

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer-Verlag Berlin Heidelberg 1981

  • Softcover ISBN: 978-3-642-81683-3Published: 21 December 2011

  • eBook ISBN: 978-3-642-81681-9Published: 06 December 2012

  • Series ISSN: 0080-0015

  • Series E-ISSN: 2197-6767

  • Edition Number: 1

  • Number of Pages: VI, 112

  • Number of Illustrations: 7 b/w illustrations

  • Topics: Oncology, Radiotherapy, Gastroenterology

Publish with us

Policies and ethics

Back to top

Search

Navigation